Vendor Intelligence Report: Pinecrest Peptide

Published 13 Jun 2026. 22-page investigative report on who is behind Pinecrest Peptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 5 Finnrick lab tests, the overall pass rate is 60%, with 3 pass / 0 fail in the scored set. Pinecrest is a Retatrutide-only testing story attached to a higher-risk identity and fulfillment file. Retatrutide is the only product with Finnrick support and sits in a middle band; non-Retatrutide products should be treated as unverified by Finnrick data.

The strongest public records tie Pinecrest to a GlobalSources supplier account for ZHM Peptide and a Hebei trading company incorporated in August 2025, not to a verified Western company. Those records sit beside older-history, GMP/ISO, overseas-warehouse, and factory-capacity claims; the full report reconciles the SGS registration, serviced-office address, new privacy-shielded domain, closed prior Pinecrest site, and absent US customs trail under the searched names.

The sharpest risk signal is reputational, not just analytical. Trustpilot, MESO-Rx, GLP-1 Forum, and Reddit materials describe a recurring post-payment sequence: responsive selling, irreversible payment rails, customs or insurance friction, added reship demands, and ghosting. Brand overlap across Pinecrest, ZHM, Xingtai Jinsheng, PINECREST PEPTIDE CO.,LIMITED, Rethel, and community-linked MGY/PeptideFacility/Jingshen names further weakens authenticity checks.

Buyer read: Retatrutide is the only plausible Pinecrest comparison point, but the record is short, methodology-sensitive, and weakened by fill-accuracy variability and missing batch identifiers. For the rest of the catalog, compare against vendors with peptide-specific testing, portal-verifiable COAs, batch IDs, and payment recourse.

Inside the full report:

  • Appendix A lab breakdown, methodology-divergence charts, and Retatrutide trajectory
  • SGS/GlobalSources registration exhibits tying Pinecrest to Xingtai Jinsheng Trading Co., Ltd.
  • Claim-verification analysis for GMP/ISO, factory, warehouse, and company-age statements
  • Brand/domain analysis covering Pinecrest, ZHM, Jinsheng, Rethel, and related forum-linked names
  • Trustpilot, MESO-Rx, GLP-1 Forum, and Reddit exhibits with transaction-pattern analysis
  • Dead-end checks across US registries, OpenCorporates, Wayback, and ImportYeti

Risk assessment

  • Post-payment fraud and customs-fee demand risk — high: Trustpilot, MESO-Rx, GLP-1 Forum, and Reddit reports describe payment followed by customs or insurance fee demands, ghosting, or non-delivery.
  • Corporate identity and manufacturing-claim misrepresentation risk — high: Verified records show a China trading company incorporated August 14, 2025, while listings claim older establishment, long experience, GMP and ISO manufacturing, and major factory capacity.
  • Brand-confusion and authenticity-verification risk — high: Pinecrest, ZHM, Xingtai Jinsheng, PINECREST PEPTIDE CO.,LIMITED, Rethel, and a separate ShanDong Juan Pinecrest listing create unclear official-channel and copycat risk.
  • COA and batch-traceability risk — high: Community reports allege non-verifying Janoshik COAs; Finnrick-tested Retatrutide vials were reported without batch IDs, preventing vial-to-COA matching.
  • Retatrutide-specific fill-accuracy and methodology-sensitivity risk — medium: Applies to Retatrutide: Finnrick shows 5 total tests with 3 pass / 0 fail and an 82% current rating, but field extraction noted fill variability and no batch IDs.
  • Irreversible-payment buyer-protection risk — medium: Buyer reports and listings identify cryptocurrency, Chime, T/T wire, or Bitcoin, reducing refund leverage when disputes arise.